Cholinergic modulation of spatial learning in mice in a Morris-type water maze.
Injection of the centrally active muscarinic antagonist scopolamine i.p. 20 min pre-test at 3 mg/kg but not at 1 mg/kg, impaired spatial learning of a Morris-type water maze adapted for mice. Both doses caused hyperactivity. D-amphetamine (3 mg/kg, i.p.), which also caused hyperactivity, did not impair spatial learning nor did methylscopolamine (3 mg/kg, i.p.). In a cued version of the water maze, apart from a temporary disturbance on day 1, scopolamine (3 mg/kg) and control groups behaved similarly, indicating that scopolamine-induced place learning deficits are not due to changes in swimming ability, motivation or ability to use proximal cues. Physostigmine (0.1 and 0.2 mg/kg, i.p.) and oxotremorine (0.02 mg/kg but not 0.01 mg/kg, i.p.) antagonized the deficits in the swimming maze. Neither drug affected the scopolamine hyperactivity despite causing hypoactivity per se. In contrast, the peripherally acting cholinergic drug neostigmine was inactive against scopolamine in either test at 0.1 mg/kg. THA (2-8 mg/kg, i.p.), RS86 (0.25-1 mg/kg, i.p.) and nicotine (1 and 3 mg/kg, i.p.) were also unable to antagonize the scopolamine effect. These studies show that scopolamine disrupts acquisition of spatial rather than cued learning in mice in a Morris-type water maze and that this effect appears to be mediated centrally and can be dissociated from drug-induced hyperactivity. Moreover, this deficit can be reversed with certain cholinergic agents.
Lamberty
Y
Y
UCB, Pharmaceutical Sector, Chemin du Foriest, Braine-l'Alleud, Belgium.
Gower
A J
AJ
D000818:Animals; D003463:Cues; D003913:Dextroamphetamine / Q000494:pharmacology; D005260:Female; D007858:Learning / Q000187:drug effects*; D051379:Mice; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D019832:N-Methylscopolamine; D009388:Neostigmine / Q000494:pharmacology; D010095:Oxotremorine / Q000494:pharmacology; D010275:Parasympathetic Nervous System / Q000187:drug effects / Q000502:physiology*; D010276:Parasympatholytics / Q000494:pharmacology; D010277:Parasympathomimetics / Q000494:pharmacology*; D010830:Physostigmine / Q000494:pharmacology; D012601:Scopolamine / Q000494:pharmacology; D012602:Scopolamine Derivatives / Q000494:pharmacology; D013028:Space Perception / Q000187:drug effects*
D010276:Parasympatholytics; D010277:Parasympathomimetics; D012602:Scopolamine Derivatives; D009388:Neostigmine; D010095:Oxotremorine; D010830:Physostigmine; D012601:Scopolamine; D003913:Dextroamphetamine; D019832:N-Methylscopolamine